Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Simple item page
dc.contributor.authorNickerson, Peter W.
dc.contributor.authorBöhmig, Georg A.
dc.contributor.authorChadban, Steve
dc.contributor.authorKumar, Deepali
dc.contributor.authorMannon, Roslyn B.
dc.contributor.authorvan Gelder, Teun
dc.contributor.authorLee, James C.
dc.contributor.authorAdler, Scott
dc.contributor.authorChong, Edward
dc.contributor.authorDjamali, Arjang
dc.date.accessioned2023-01-01T04:54:49Z
dc.date.issued2022-12-22
dc.date.updated2023-01-01T04:54:50Z
dc.description.abstractBackground Chronic active antibody-mediated rejection (AMR) is a major cause of graft loss with no approved drugs for its treatment. Currently, off-label regimens are used, reflecting the high unmet need for effective therapies based on well-controlled trials. Clazakizumab is a high-affinity, humanized monoclonal antibody that binds interleukin-6 and decreases donor-specific antibody (DSA) production and inflammation. Phase 2 pilot studies of clazakizumab in kidney transplant recipients with chronic active AMR suggest modulation of DSA, stabilization of glomerular filtration rate (GFR), and a manageable safety profile. We report the design of the Phase 3 IMAGINE study (NCT03744910) to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active AMR. Methods IMAGINE is a multicenter, double-blind trial of approximately 350 kidney transplant recipients with chronic active AMR (Banff chronic glomerulopathy [cg] >0 with concurrent positive human leukocyte antigen DSA) randomized 1:1 to receive clazakizumab or placebo (12.5 mg subcutaneous once every 4 weeks). The event-driven trial design will follow patients until 221 occurrences of all-cause graft loss are observed, defined as return to dialysis, graft nephrectomy, re-transplantation, estimated GFR (eGFR) <15 mL/min/1.73m2, or death from any cause. A surrogate for graft loss (eGFR slope) will be assessed at 1 year based on prior modeling validation. Secondary endpoints will include measures of pharmacokinetics/pharmacodynamics. Recruitment is ongoing across North America, Europe, Asia, and Australia. Discussion IMAGINE represents the first Phase 3 clinical trial investigating the safety and efficacy of clazakizumab in kidney transplant recipients with chronic active AMR, and the largest placebo-controlled trial in this patient population. This trial includes prognostic biomarker enrichment and uniquely utilizes the eGFR slope at 1 year as a surrogate endpoint for graft loss, which may accelerate the approval of a novel therapy for patients at risk of graft loss. The findings of this study will be fundamental in helping to address the unmet need for novel therapies for chronic active AMR. Trial registration ClinicalTrials.gov NCT03744910 Registered on November 19, 2018.
dc.identifier.citationTrials. 2022 Dec 22;23(1):1042
dc.identifier.doi10.1186/s13063-022-06897-3
dc.identifier.urihttp://hdl.handle.net/1993/37041
dc.language.isoeng
dc.language.rfc3066en
dc.publisherBMC
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.subjectChronic active antibody-mediated rejection
dc.subjectClazakizumab
dc.subjectEstimated glomerular filtration rate
dc.subjectKidney transplantation
dc.titleClazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design
dc.typeJournal Article
local.author.affiliationRady Faculty of Health Sciences::Max Rady College of Medicine::Department of Internal Medicine
oaire.citation.issue1042
oaire.citation.titleTrials
oaire.citation.volume23
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13063_2022_Article_6897.pdf
Size:
1.66 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship